about
MicroRNA Targeting to Modulate Tumor MicroenvironmentStromal Targets for Fluorescent-Guided Oncologic SurgeryClinical Advancements in the Targeted Therapies against Liver Fibrosis.Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injuryDetecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility.Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In VivoTumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration.Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivoInterferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice.Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis.Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles.SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo.Nanomedicine Strategies to Target Tumor-Associated Macrophages.Drug targeting to myofibroblasts: Implications for fibrosis and cancer.PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection.A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier.Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors.Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology.Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model.Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury.MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor.Editorial: Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment.Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.Targeting tumor stromal cells through a PDGF-beta receptor binding carrier.Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth.Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis.Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats.Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases.Fibrosis imaging: Current concepts and future directions.Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer.Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.Fibroblasts and extracellular matrix: Targeting and therapeutic tools in fibrosis and cancer.Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery.Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer.
P50
Q26770275-886AF9CD-63D0-4740-A0F9-5C96EEEFD2E0Q26774497-61478611-BC1D-4FEC-9727-18EC8DDE7AE6Q28078684-755FDC28-9ECA-4B26-9CD0-A8A9D7D1970CQ28486225-05898D40-DAE8-4D6D-AD80-FC9D3E922942Q30238465-10CDB793-FFF0-4C9B-BC81-97284C62BE99Q35108259-629540AF-2EE4-4145-8186-2C9831D4BDE2Q35647851-E9029A3F-5EE8-47F5-B577-15AE46EFB5F9Q36129580-96E033FA-453E-4A06-9E98-D89085995C04Q37478648-5DBA4B50-D8B7-46A7-95AB-40EA09E08C55Q37688040-0C6FC2CF-0693-4089-8351-A2FF6EA9008BQ37960141-57EBAEDB-83A9-4171-8671-5F2A29883716Q38702943-E8A8E74A-C10C-4D74-BE55-27C3D52D37D4Q38812340-27FD7D6F-A423-48DC-979D-8288B42BB5E5Q38885068-F39B6FAC-5860-4AC4-AE37-4A212F980168Q38890829-7BF5D380-B4F0-4E48-8599-C22F3F4FD466Q39283111-4E235316-1AB5-459D-BBE9-BEFC3CC56BE0Q39442536-A56317FA-C324-4927-9712-E4B5E09AD0EFQ39526531-11329A1C-D1CE-4F03-BCB3-6D2AE4ED6CFBQ39555372-9846F77E-4A8D-42E0-A7CD-D0A6ED5B11D9Q39719552-E81097B1-BF31-452B-9C41-BC972877740CQ40027110-B70442AE-F4D2-428B-AFD1-FF0ECFE171D6Q40046908-3E192B2C-C405-4F72-858B-C940CEFC1D13Q40230167-99B821B6-3440-4B30-8763-E57623A9A02DQ40293690-179B5B3B-4A7F-4DDF-933B-15197A99281BQ41886605-55BA655E-952A-4FFB-9F27-802B3EA9C5D7Q42425474-8858749D-4D87-4C8A-A085-C1EA2C35603AQ42783558-A0C691FA-BAD4-4194-AF57-E38D20B2BB84Q42789129-B116B44F-6BDC-4320-A220-EB138C4C7802Q42811267-BF446CBB-705D-4AFF-A7FA-FEED00D8982DQ42831268-3CF50E79-4A40-4F3E-8871-6E41373EAA8EQ42832729-9D6B2EFF-FC28-4AAD-AD88-EA98B3C74969Q46415767-B48A5402-BC24-4FC8-9453-C134A217FF25Q46720179-77BBDADE-BED5-4F89-8BEA-78D7AEB66D46Q47139621-920E0C9F-C8C3-47F1-96A4-CF83055BE7A7Q47376188-B549330A-D89F-4CBE-AC5F-3946D7776571Q47608207-A4946363-10BC-4F65-9ADF-B107D0D37426Q48595289-BB131F6B-D75F-41D7-B9E0-9104FF66B74CQ49392109-F8AA5083-3D7C-4D2D-A855-3BD761B77A3FQ50134534-CE4E5C67-ED61-4E24-8228-E7566C381480Q50169246-EBBAC862-E677-4185-98D2-5C4A207F4C08
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jai Prakash
@ast
Jai Prakash
@en
Jai Prakash
@es
Jai Prakash
@sl
জয় প্রকাশ
@bn
type
label
Jai Prakash
@ast
Jai Prakash
@en
Jai Prakash
@es
Jai Prakash
@sl
জয় প্রকাশ
@bn
prefLabel
Jai Prakash
@ast
Jai Prakash
@en
Jai Prakash
@es
Jai Prakash
@sl
জয় প্রকাশ
@bn
P106
P21
P2798
P31
P496
0000-0003-1050-650X
P569
2000-01-01T00:00:00Z
P735
P7449
PRS1331627